Fedulov Artemiy

Mr. Fedulov Artemiy

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
OSOlga A. Smirnova
Olga A. Smirnova
OIOlga Ivanova
Olga Ivanova
FMFurkat Mukhtarov
Furkat Mukhtarov
VVVladimir Valuev-Elliston
Vladimir Valuev-Elliston
FAFedulov Artemiy
Fedulov Artemiy
Alexander V. IvanovAlexander V. Ivanov
Alexander V. Ivanov
Hepatitis delta virus (HDV) is a viroid-like satellite that may co-infect individuals together with hepatitis B virus (HBV), as well as cause superinfection by infecting patients with chronic hepatitis B (CHB). Being a defective virus, HDV requires HBV structural proteins for virion production. Although the virus encodes just two forms of its single antigen, it enhances the progression of liver disease to cirrhosis in CHB patients and increases the incidence of hepatocellular carcinoma. HDV pathogenesis so far has been attributed to virus-induced humoral and cellular immune responses, while other factors have been neglected. Here, we evaluated the impact of the virus on the redox status of hepatocytes, as oxidative stress is believed to contribute to the pathogenesis of various viruses, including HBV and hepatitis C virus (HCV). We show that the overexpression of large HDV antigen (L-HDAg) or autonomous replication of the viral genome in cells leads to increased production of reactive oxygen species (ROS). It also leads to the upregulated expression of NADPH oxidases 1 and 4, cytochrome P450 2E1, and ER oxidoreductin 1α, which have previously been shown to mediate oxidative stress induced by HCV. Both HDV antigens also activated the Nrf2/ARE pathway, which controls the expression of a spectrum of antioxidant enzymes. Finally, HDV and its large antigen also induced endoplasmic reticulum (ER) stress and the concomitant unfolded protein response (UPR). In conclusion, HDV may enhance oxidative and ER stress induced by HBV, thus aggravating HBV-associated pathologies, including inflammation, liver fibrosis, and the development of cirrhosis and hepatocellular carcinoma.

17 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FAFedulov Artemiy
Fedulov Artemiy
OIOlga Ivanova
Olga Ivanova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
DKDmitry Kostyushev
Dmitry Kostyushev
Alexander V. IvanovAlexander V. Ivanov
Alexander V. Ivanov
Hepatitis B virus (HBV is a widely spread human pathogen that accounts for 250 mln cases of chronic hepatitis worldwide. Hepatitis delta virus (HDV) is its viroid-like satellite that substantially aggravates liver disease. Importantly, both HBV and HDV are oncogenic viruses. The development of new antivirals and investigation of virus pathogenesis is limited by absence of effective cellular and animal models. Currently used cell models are based on human primary hepatocytes, liver progenitor HepaRG cells, hepatocyte-like cells derived from iPS or various hepatoma cells overexpressing putative NTCP receptor. However, in most of these models a majority of cells are non-permissive. In this review we briefly review these models, summarize approaches to increase infection rates, and discuss data about proviral and antiviral (restriction) host factors. The data discussed suggest that rates of HBV and HDV infection are limited by hepatocyte polarization, insufficient expression of the NTPC receptor as well as existence of additional co-receptors and restriction factors that can act mostly on virus entry stage.

22 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MZMartin А Zenov
Martin А Zenov
DYDmitry Vasilevich Yanvarev
Dmitry Vasilevich Yanvarev
OIOlga Ivanova
Olga Ivanova
EDEkaterina A. Denisova
Ekaterina A. Denisova
MGMikhail V. Golikov
Mikhail V. Golikov
Alexander V. IvanovAlexander V. Ivanov
Alexander V. Ivanov
Poliovirus represents an oncolytic agent human glioblastoma - one of the most aggressive types of cancer. Since interference of viruses with metabolic and redox pathways is often linked to their pathogenesis, drugs targeting metabolic enzymes are regarded as potential enhancers of oncolysis. Our goal was to reveal imprint of poliovirus on metabolism of glioblastoma cells lines and to assess dependence of the virus on these pathways. Using GC-MS, HPLC and Seahorse techniques, we show that poliovirus interferes with amino acid, purine and polyamine metabolism, mitochondrial respiration and glycolysis. However, many of these changes are cell line- and culture medium-dependent. Inhibitors of metabolic enzymes affected neither poliovirus replication nor cytopathogenic effect with the exception of inhibitors of polyamine biosynthesis and pyruvate import into mitochondria that exhibited antiviral activity. We also demonstrate that poliovirus does not interfere with production of superoxide anions or with levels of H2O2 showing absence of oxidative stress during the infection. So, poliovirus pathogenesis is not associated with alterations of cell metabolism or redox status, and pharmacological inhibitors of metabolic enzymes cannot be used to boost its oncolytic activity.